CERYVYN THERAPEUTICS LIMITED ADR
WKN: A2QEW7 | ISIN: US68386J2087 | Ticker-Symbol: UKJ2Siehe auch CERYVYN THERAPEUTICS LIMITED
Frankfurt
17.03.25 | 08:52
3,000 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.09. | CERYVYN THERAPEUTICS LIMITED: Notification regarding unquoted securities - CYV | - | ASX | ||
| 08.09. | CERYVYN THERAPEUTICS LIMITED: Proposed issue of securities - CYV | - | ASX | ||
| 01.09. | CERYVYN THERAPEUTICS LIMITED: Proposed issue of securities - CYV | - | ASX | ||
| 31.08. | CERYVYN THERAPEUTICS LIMITED: Appendix 4G and Corporate Governance Statement | - | ASX | ||
| 31.08. | CERYVYN THERAPEUTICS LIMITED: Appendix 4E and 2026 Annual Report | - | ASX | ||
| 21.08. | CERYVYN THERAPEUTICS LIMITED: Notification regarding unquoted securities - CYV | 1 | ASX | ||
| 27.07. | CERYVYN THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| CERYVYN THERAPEUTICS LIMITED ADR Aktie jetzt für 0€ handeln | |||||
| 17.07. | CERYVYN THERAPEUTICS LIMITED: Update to Executive Chair Remuneration Arrangements | - | ASX | ||
| 13.07. | CERYVYN THERAPEUTICS LIMITED: Notification of cessation of securities - CYV | - | ASX | ||
| 10.07. | CERYVYN THERAPEUTICS LIMITED: Change of Company's Constitution | - | ASX | ||
| 08.07. | OPTHEA LIMITED: Change of Company Name, ASX Code and Registered Office | 1 | ASX | ||
| 03.07. | OPTHEA LIMITED: Results of EGM | - | ASX | ||
| 25.06. | OPTHEA LIMITED: Change of Director's Interest Notice - JL | - | ASX | ||
| 25.06. | OPTHEA LIMITED: Notification regarding unquoted securities - OPT | - | ASX | ||
| 24.06. | OPTHEA LIMITED: Becoming a substantial holder | - | ASX | ||
| 22.06. | OPTHEA LIMITED: Ceasing to be a substantial holder | - | ASX | ||
| 19.06. | OPTHEA LIMITED: Change of Director's Interest Notice - KC & LG | - | ASX | ||
| 18.06. | Dr Boreham's Crucible: Opthea seeks a second act with rare lung disease program | 1 | Stockhead | ||
| 18.06. | OPTHEA LIMITED: Ceasing to be a substantial holder | - | ASX | ||
| 18.06. | OPTHEA LIMITED: Ceasing to be a substantial holder | - | ASX |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 10,630 | -2,48 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 4,425 | +1,96 % | Cosciens Biopharma Inc (2): Cosciens closes second tranche of debenture offering | ||
| HALOZYME THERAPEUTICS | 97,44 | -0,49 % | Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 | SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 10,900 | -0,18 % | AbCellera-Aktie mit +18% - neues Allzeithoch möglich? | Die AbCellera-Aktie hat zuletzt erneut einen kräftigen Kurssprung hingelegt. Am gestrigen Handelstag ging es um +17,81% nach oben. Damit setzt sich die außergewöhnliche Rallye fort: Seit dem lokalen... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 332,20 | 0,00 % | ROUNDUP/'WSJ': US-Investor Elliot steigt bei Sartorius-Großaktionär Bio-Rad ein | NEW YORK (dpa-AFX) - Der US-Investor Elliott hat laut einem Medienbericht eine beachtliche Beteiligung an dem Sartorius-Großaktionär Bio-Rad Laboratories aufgebaut. Der aktivistische Investor wolle... ► Artikel lesen | |
| GLOW LIFETECH | 0,021 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Reports Positive Q2 2026 Results; Revenue Growth Continues for 12th Consecutive Quarter | Toronto, Ontario--(Newsfile Corp. - August 25, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the second... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy | Company expands team, university partnerships, and internship programs to build long-term biologics talent pipeline.TUSTIN, Calif., May 18, 2026 /PRNewswire/ -- Avid Bioservices, a leading... ► Artikel lesen | |
| BIOLINERX | 1,920 | -6,80 % | BioLineRx Ltd.: BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update | - Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September -
- Announced new data... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 3,118 | -1,64 % | Minerva Neurosciences, Inc: Minerva Neurosciences to Participate in Two Upcoming Investor Conferences | BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 3,500 | -3,31 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights | Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026
Cash, cash equivalents and short-term... ► Artikel lesen | |
| INNOVENT BIOLOGICS | 11,512 | +5,11 % | Innovent Biologics: Innovent Announces 2026 Interim Results and Business Updates | Transforming from Regional Leader to Global Premier:
A Clear Strategic Path for Growth and Globalization
SAN FRANCISCO and SUZHOU, China, Aug. 25, 2026 /PRNewswire/... ► Artikel lesen | |
| OVID THERAPEUTICS | 2,440 | +3,39 % | Ovid Therapeutics auf H.C. Wainwright Konferenz: Pipeline-Strategie für Hirnerkrankungen im Fokus | ||
| COCRYSTAL | 1,060 | +2,91 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors | BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| GEOVAX LABS | 0,360 | -2,20 % | EQS-News: GeoVax, Inc.: GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models 21.09.2026 / 14:37 CET/CEST
The... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 5,930 | +2,24 % | Precision BioSciences stellt auf H.C. Wainwright Konferenz Zwei-Säulen-Strategie vor |
Das Unternehmen CERYVYN THERAPEUTICS LIMITED ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,000 Euro. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERYVYN THERAPEUTICS LIMITED ADR finden Sie auf Wallstreet Online.